Genethon, member of the Biotherapies Institute for Rare Diseases, is at the center of national and international networks

To accelerate research and produce the medicines of tomorrow, Genethon is following a policy of first-class, national and international partnerships in Europe, the USA and Japan.

Genethon also coordinates or participates in national and international networks, enabling it to ensure the highest standards of preclinical and clinical development for every target pathology.

Our goal is to bring to patients these innovative treatments, at a controlled and fair price; hence our requirement at every stage of the development of our products.